Drug Profile
Autolymphocyte therapy - Cellcor
Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Cytogen Corporation
- Class Cell therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Malignant melanoma; Prostate cancer; Renal cancer
Most Recent Events
- 08 Jan 2001 Discontinued-I for Malignant melanoma (Infusion)
- 08 Jan 2001 Discontinued-I for Prostate cancer (Infusion)
- 08 Jan 2001 Discontinued-I for Renal cancer in Netherlands (Infusion)